Based on 7 analysts giving stock ratings to Immuneering Corp in the past month.
In the current month, IMRX has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMRX average Analyst price target in the last month is 17.000.
Based on analysts' estimates, IMRX EPS is projected to reach -0.346 in FY2026Q4, following reported EPS of -0.374 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.37, while Immuneering CorpIMRX's earnings per share (EPS) for the previous quarter was USD -0.27. EPS for the next quarter is expected at USD -0.35.